| { |
| "sku": "HLT011", |
| "module": "Clinical Trial Eligibility Engine", |
| "generated_at": "2026-05-17T19:32:31.716145", |
| "seed": 42, |
| "n_patients": 1500, |
| "n_trial_templates": 15, |
| "eligibility": { |
| "overall_rate": 0.78, |
| "mean_score": 0.701, |
| "score_std": 0.177 |
| }, |
| "enrollment": { |
| "total_enrolled": 467, |
| "unique_patients": 467, |
| "trials_meeting_target": 0, |
| "mean_screen_fail_rate": 0.315 |
| }, |
| "endpoints": { |
| "total_assessments": 2689, |
| "responder_rate_active_arm": 0.711, |
| "protocol_deviation_rate": 0.076, |
| "withdrawal_rate": 0.008 |
| }, |
| "trials": [ |
| { |
| "trial_id": "TRIAL-GD-001", |
| "disease": "Gaucher Disease Type 1", |
| "phase": "Phase 3", |
| "n_target": 120 |
| }, |
| { |
| "trial_id": "TRIAL-SMA-001", |
| "disease": "Spinal Muscular Atrophy", |
| "phase": "Phase 3", |
| "n_target": 80 |
| }, |
| { |
| "trial_id": "TRIAL-CF-001", |
| "disease": "Cystic Fibrosis", |
| "phase": "Phase 3", |
| "n_target": 200 |
| }, |
| { |
| "trial_id": "TRIAL-DMD-001", |
| "disease": "Duchenne Muscular Dystrophy", |
| "phase": "Phase 2/3", |
| "n_target": 60 |
| }, |
| { |
| "trial_id": "TRIAL-HD-001", |
| "disease": "Huntington Disease", |
| "phase": "Phase 2/3", |
| "n_target": 100 |
| }, |
| { |
| "trial_id": "TRIAL-FAB-001", |
| "disease": "Fabry Disease", |
| "phase": "Phase 3", |
| "n_target": 90 |
| }, |
| { |
| "trial_id": "TRIAL-MFS-001", |
| "disease": "Marfan Syndrome", |
| "phase": "Phase 3", |
| "n_target": 150 |
| }, |
| { |
| "trial_id": "TRIAL-HEM-001", |
| "disease": "Hemophilia A", |
| "phase": "Phase 3", |
| "n_target": 70 |
| }, |
| { |
| "trial_id": "TRIAL-PKD-001", |
| "disease": "ADPKD", |
| "phase": "Phase 3", |
| "n_target": 180 |
| }, |
| { |
| "trial_id": "TRIAL-OI-001", |
| "disease": "Osteogenesis Imperfecta", |
| "phase": "Phase 2/3", |
| "n_target": 100 |
| }, |
| { |
| "trial_id": "TRIAL-TS-001", |
| "disease": "Tuberous Sclerosis", |
| "phase": "Phase 3", |
| "n_target": 80 |
| }, |
| { |
| "trial_id": "TRIAL-SCD-001", |
| "disease": "Sickle Cell Disease", |
| "phase": "Phase 3", |
| "n_target": 75 |
| }, |
| { |
| "trial_id": "TRIAL-NPC-001", |
| "disease": "Niemann-Pick Type C", |
| "phase": "Phase 2/3", |
| "n_target": 50 |
| }, |
| { |
| "trial_id": "TRIAL-LCA-001", |
| "disease": "Leber Congenital Amaurosis", |
| "phase": "Phase 3", |
| "n_target": 40 |
| }, |
| { |
| "trial_id": "TRIAL-CAH-001", |
| "disease": "Congenital Adrenal Hyperplasia", |
| "phase": "Phase 3", |
| "n_target": 110 |
| } |
| ] |
| } |
